A number of factors related to and independent of tumor stage help to determine the need for adjuvant therapies in patients with EC. The accurate and consistent reporting of these pathologic parameters is vital to ensure optimal patient management.
2. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016;27:16–41.
4. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.
5. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017;123:802–13.
6. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC Cohorts. Clin Cancer Res 2016;22:4215–24.
7. de Boer SM, Wortman BG, Bosse T, et al. Clinical consequences of upfront pathology
review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol 2018;29:424–30.
8. Manion E, Cohen MB, Weydert J. Mandatory second opinion in surgical pathology
referral material: clinical consequences of major disagreements. Am J Surg Pathol 2008;32:732–7.
9. Chafe S, Honore L, Pearcey R, et al. An analysis of the impact of pathology
review in gynecologic cancer. Int J Radiat Oncol Biol Phys 2000;48:1433–8.
10. Khalifa MA, Dodge J, Covens A, et al. Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy. Gynecol Oncol 2003;90:425–30.
11. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma
. Int J Gynecol Pathol 2007;26:115–23.
12. McCluggage WG, Hirschowitz L, Wilson GE, et al. Significant variation in the assessment of cervical involvement in endometrial carcinoma
: an interobserver variation study. Am J Surg Pathol 2011;35:289–94.
13. Creasman W. Revised FIGO staging
for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109.
14. Brierley JE, Gospodarowicz MKE, Wittekind CE. TNM classification of malignant tumours. 8th ed.
15. Pecorelli S. Revised FIGO staging
for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103–4.
16. McCluggage WG, Colgan T, Duggan M, et al. Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 2013;32:45–65.
17. Drake R, Vogl AW, Mitchell AWM. Gray’s Anatomy for Students, 3rd ed. Philadelphia: Churchill Livingstone; 2014.
18. Williams JW, Hirschowitz L. Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas. Int J Gynecol Pathol 2006;25:59–64.
19. Hirschowitz L, Nucci M, Zaino RJ. Problematic issues in the staging
of endometrial, cervical and vulval carcinomas. Histopathology 2013;62:176–202.
20. Soslow RA. Practical issues related to uterine pathology
, frozen section, artifacts, and Lynch syndrome. Mod Pathol 2016;29(suppl 1):S59–77.
21. Jacques SM, Lawrence WD. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases. Gynecol Oncol 1990;37:401–7.
22. Hanley KZ, Dustin SM, Stoler MH, et al. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol 2010;29:445–51.
23. Matsuo K, Cahoon SS, Gualtieri M, et al. Significance of adenomyosis on tumor progression and survival outcome of endometrial cancer. Ann Surg Oncol 2014;21:4246–55.
24. Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis
. Gynecol Oncol 1993;49:197–201.
25. Ismiil N, Rasty G, Ghorab Z, et al. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol 2007;11:252–7.
26. Ismiil ND, Rasty G, Ghorab Z, et al. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma. Int J Gynecol Pathol 2007;26:278–83.
27. Taneichi A, Fujiwara H, Takahashi Y, et al. Influences of uterine adenomyosis on muscle invasion and prognosis
of endometrioid adenocarcinoma. Int J Gynecol Cancer 2014;24:1429–33.
28. Ganesan R, Singh N, McCluggage WG. Standards and datasets for reporting cancers: dataset for histological reporting of endometrial cancer. The Royal College of Pathologists.
29. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003;22:324–33.
30. Stewart CJ, Brennan BA, Leung YC, et al. MELF
pattern invasion in endometrial carcinoma
: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology
31. Han G, Lim D, Leitao MM Jr, et al. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology 2014;64:389–98.
32. Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol 2016;29(suppl 1):S29–44.
33. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55–65.
34. Pitson G, Colgan T, Levin W, et al. Stage II endometrial carcinoma
: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys 2002;53:862–7.
35. Zaino RJ, Abendroth C, Yemelyanova A, et al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecol Oncol 2013;128:83–7.
36. Orezzoli JP, Sioletic S, Olawaiye A, et al. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion
. Gynecol Oncol
37. Roma AA, Rybicki LA, Barbuto D, et al. Risk factor analysis of recurrence in low-grade endometrial adenocarcinoma. Hum Pathol 2015;46:1529–39.
38. Tambouret R, Clement PB, Young RH. Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIb endometrial carcinoma
liable to be misinterpreted as an independent carcinoma or a benign lesion. Am J Surg Pathol 2003;27:1080–8.
39. Ferriss JS, Brix W, Tambouret R, et al. Cervical stromal invasion
predicting survival in endometrial cancer. Obstet Gynecol 2010;116:1035–41.
40. Stewart CJ, Hillery S, Platell C, et al. Assessment of serosal invasion and criteria for the classification of pathological (p) T4 staging
in colorectal carcinoma: confusions, controversies and criticisms. Cancers (Basel) 2011;3:164–81.
41. Connell PP, Rotmensch J, Waggoner S, et al. The significance of adnexal involvement
in endometrial carcinoma
. Gynecol Oncol 1999;74:74–9.
42. Anglesio MS, Wang YK, Maassen M, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst 2016;108:djv428.
43. Schultheis AM, Ng CK, De Filippo MR, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst 2016;108:djv427.
44. Stewart CJR, Crum CP, McCluggage WG, et al. Guidelines to aid in the distinction of endometrial and endocervical carcinomas, and the distinction of independent primary carcinomas of the endometrium and adnexa from metastatic spread between these and other sites. Int J Gynecol Pathol
2018. In press.
45. Krizova A, Clarke BA, Bernardini MQ, et al. Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review. Am J Surg Pathol 2011;35:115–26.
46. Delair D, Soslow RA, Gardner GJ, et al. Tumoral displacement into fallopian tubes in patients undergoing robotically assisted hysterectomy for newly diagnosed endometrial cancer. Int J Gynecol Pathol 2013;32:188–92.
47. Snyder MJ, Bentley R, Robboy SJ. Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol 2006;25:155–60.
48. Felix AS, Brinton LA, McMeekin DS, et al. Relationships of tubal ligation to endometrial carcinoma
stage and mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst 2015;107:1–9.
49. Stewart CJ, Doherty DA, Havlat M, et al. Transtubal spread of endometrial carcinoma
: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis. Pathology
50. Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol 2015;39:35–51.
51. Kommoss F, Faruqi A, Gilks CB, et al. Uterine serous carcinomas frequently metastasize to the fallopian tube and can mimic serous tubal intraepithelial carcinoma. Am J Surg Pathol 2017;41:161–70.
52. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009;28:308–15.
53. Stewart CJ, Armstrong M, Brennan BA, et al. Coexisting serous carcinoma of the endometrium and the fallopian tube. Int J Gynecol Pathol 2010;29:278–81.
54. Lee TS, Kim JW, Kim DY, et al. Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci 2010;25:552–6.
55. Yen MS, Yuan CC, Wang PH, et al. Parametrial tumor spreading patterns in cervix cancer patients treated by radical hysterectomy. Int J Gynaecol Obstet 2003;80:145–51.
56. Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma
. Obstet Gynecol 2010;116:1027–34.
57. Giede C, Le T, Power P, et al. The role of surgery in endometrial cancer. J Obstet Gynaecol Can 2013;35:370–4.
58. ASTEC Study Group, Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125–36.
59. Bendifallah S, Koskas M, Ballester M, et al. The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. Am J Obstet Gyneco
60. Agar N, Philippe AC, Bourdel N, et al. Morbidity of pelvic lymphadenectomy and para-aortic lymphadenectomy in endometrial cancer. Bull Cancer 2015;102:428–35.
61. Ballester M, Dubernard G, Bats AS, et al. Comparison of diagnostic accuracy of frozen section with imprint cytology for intraoperative examination of sentinel lymph node in early-stage endometrial cancer: results of Senti-Endo study. Ann Surg Oncol 2012;19:3515–21.
62. Bernardini MQ, Murphy JK. Issues surrounding lymphadenectomy in the management of endometrial cancer. J Surg Oncol 2009;99:232–41.
63. Yasunaga M, Yamasaki F, Tokunaga O, et al. Endometrial carcinomas with lymph node involvement: novel histopathologic factors for predicting prognosis
. Int J Gynecol Pathol 2003;22:341–6.
64. Lutman CV, Havrilesky LJ, Cragun JM, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma
with high-risk histology. Gynecol Oncol 2006;102:92–7.
65. Tomisato S, Yamagami W, Susumu N, et al. Clinicopathological study on para-aortic lymph node metastasis without pelvic lymph node metastasis in endometrial cancer. J Obstet Gynaecol Res 2014;40:1733–9.
66. Abu-Rustum NR, Iasonos A, Zhou Q, et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma
? Am J Obstet Gynecol 2008;198:457.e1–5; discussion 5-6.
67. Schmolze D, Awtrey CS, Hecht JL. Value of additional level sections in the evaluation of lymph nodes for endometrial carcinoma staging
. Am J Clin Pathol 2013;140:516–8.
68. Fleming ND, Soliman PT, Westin SN, et al. Impact of lymph node ratio and adjuvant therapy in node-positive endometrioid endometrial cancer. Int J Gynecol Cancer 2015;25:1437–44.
69. Barakat R. Pattern of lymph node metastasis may define prognosis
in endometrial cancer, but will it influence treatment approach? Abstr Hematol Oncol 2001;4:3.
70. Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging
. Int J Gynecol Cancer 2013;23:964–70.
71. Ballester M, Naoura I, Chereau E, et al. Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study. Ann Surg Oncol 2013;20:407–12.
72. Darai E, Dubernard G, Bats AS, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 2015;136:54–9.
73. St Clair CM, Eriksson AG, Ducie JA, et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma
. Ann Surg Oncol 2016;23:1653–9.
74. Touhami O, Gregoire J, Renaud MC, et al. Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer. Gynecol Oncol 2017;147:549–53.
75. Touhami O, Trinh XB, Gregoire J, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol 2015;138:41–5.
76. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:459–76.e10.
77. Euscher E, Sui D, Soliman P, et al. Ultrastaging of sentinel lymph nodes in endometrial carcinoma
according to use of 2 different methods. Int J Gynecol Pathol 2018;37:242–51.
78. Winer I, Ahmed QF, Mert I, et al. Significance of lymphovascular space invasion
in uterine serous carcinoma: what matters more; extent or presence? Int J Gynecol Pathol 2015;34:47–56.
79. Folkins AK, Nevadunsky NS, Saleemuddin A, et al. Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Mod Pathol 2010;23:1073–9.
80. Kuroki J, Hasegawa K, Kato R, et al. Relationship between the classification of vascular invasion severity and the prognosis
of uterine endometrial cancer. Int J Gynecol Cancer 2003;13:47–52.
81. Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015;51:1742–50.
82. Alexander-Sefre F, Singh N, Ayhan A, et al. Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer. Gynecol Oncol 2004;92:653–9.
83. Tsuruchi N, Kaku T, Kamura T, et al. The prognostic significance of lymphovascular space invasion
in endometrial cancer when conventional hemotoxylin and eosin staining is compared to immunohistochemical staining. Gynecol Oncol 1995;57:307–12.
84. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008;26:5965–71.
85. Cetinkaya K, Atalay F, Bacinoglu A. Risk factors of lymph node metastases with endometrial carcinoma
. Asian Pac J Cancer Prev 2014;15:6353–6.
86. Masuda K, Banno K, Yanokura M, et al. Carcinoma of the lower uterine segment (LUS): clinicopathological characteristics and association with lynch syndrome. Curr Genomics 2011;12:25–9.
87. McKenney JK, Kong CS, Longacre TA. Endometrial adenocarcinoma associated with subtle lymph-vascular space invasion and lymph node metastasis: a histologic pattern mimicking intravascular and sinusoidal histiocytes. Int J Gynecol Pathol 2005;24:73–8.
88. Pavlakis K, Messini I, Vrekoussis T, et al. MELF
invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology 2011;58:966–73.
89. Quick CM, May T, Horowitz NS, et al. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol 2012;31:337–43.
90. Zaino RJ. Unusual patterns of endometrial carcinoma
and its relation to epithelial mesenchymal transition. Int J Gynecol Pathol 2014;33:357–64.
91. Kihara A, Yoshida H, Watanabe R, et al. Clinicopathologic association and prognostic value of microcystic, elongated, and fragmented (MELF
) pattern in endometrial endometrioid carcinoma. Am J Surg Pathol 2017;41:896–905.
92. Joehlin-Price AS, McHugh KE, Stephens JA, et al. The microcystic, elongated, and fragmented (MELF
) pattern of invasion: a single institution report of 464 consecutive FIGO grade 1 endometrial endometrioid adenocarcinomas. Am J Surg Pathol 2017;41:49–55.